Our CHyT-T cell therapy development platform enables powering T cells for cancer cures. We can accommodate the properties of your project and propose the most appropriate solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.
As a global contract research organization, Creative Biolabs worked on a wide range of drug discovery and development services for various disease types. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project lifecycle management, as well as real-time data to ensure the ideal outcomes.
Our CHyT Technology
Now our scientists established a superior platform to develop a novel engineered T cell therapy – CHyT-T cell therapy which is designed to incorporate the best features of TCR-T and CAR-T cell therapies, and more importantly, it overcomes the limitations of TCR-T and CAR-T. By conjugating the specific tumor antigen to the TCR complex via high-affinity scFv which can recognize the antigens on tumor cells without HLA dependence, the CHyT construct can engage the complete TCR machinery to drive fully T cell activation which is required for potent, modulated and durable tumor attack.
Our End-to-end Solutions
Final Promising CHyT-T Cell Therapy Product Candidate
Strong intellectual property; Advanced cutting-edge technologies; Global strategic partnerships
Through our full spectrum of early discovery, nonclinical and commercialization services, Creative Biolabs is committed to developing the most promising CHyT-T cell therapy product candidate for our clients.
Moving T Cell Therapy Beyond the Limits Existing in CAR-T and TCR-T Cell Therapy
Creative Biolabs is passionate about offering the valuable solutions to develop a promising cellular therapy candidate for our clients. Our goal is to promote novel T cell therapies to clinical trials for a wide range of hematologic cancers and solid tumors. We are building a team of talented and motivated scientists and technicians to pursue our commitment. If you are interested in any module of our CHyT-T cell therapy development solutions or the integrated end-to-end solutions, please don’t hesitate to contact us to learn how we can be involved in your project.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE